Zepbound beats Wegovy rival in 1st head-to-head weight loss study – National
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.…